BRPI0620243A2 - peptìdeo quimérico capaz de se ligar à pelo menos uma forma alélica da molécula hla-dr, composição farmaceutica e uso do peptìdeo - Google Patents

peptìdeo quimérico capaz de se ligar à pelo menos uma forma alélica da molécula hla-dr, composição farmaceutica e uso do peptìdeo Download PDF

Info

Publication number
BRPI0620243A2
BRPI0620243A2 BRPI0620243-8A BRPI0620243A BRPI0620243A2 BR PI0620243 A2 BRPI0620243 A2 BR PI0620243A2 BR PI0620243 A BRPI0620243 A BR PI0620243A BR PI0620243 A2 BRPI0620243 A2 BR PI0620243A2
Authority
BR
Brazil
Prior art keywords
hla
peptide
chimeric peptide
seq
binding
Prior art date
Application number
BRPI0620243-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Francisco Borras Cuesta
Sagastibelza Juan Jose Lasarte
Marta Ruiz Egozcue
Pablo Sarobe Ugarriza
Original Assignee
Proyecto Biomedicina Cima Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Biomedicina Cima Sl filed Critical Proyecto Biomedicina Cima Sl
Publication of BRPI0620243A2 publication Critical patent/BRPI0620243A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0620243-8A 2005-12-23 2006-12-19 peptìdeo quimérico capaz de se ligar à pelo menos uma forma alélica da molécula hla-dr, composição farmaceutica e uso do peptìdeo BRPI0620243A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP200503169 2005-12-23
ES200503169A ES2310072B1 (es) 2005-12-23 2005-12-23 Nuevos peptidos determinantes antigenicos t colaboradores (/dth).
PCT/ES2006/000695 WO2007074188A1 (es) 2005-12-23 2006-12-19 NUEVOS PEPTIDOS DETERMINANTES ANTIGENICOS T COLABORADORES (DTh)

Publications (1)

Publication Number Publication Date
BRPI0620243A2 true BRPI0620243A2 (pt) 2011-11-08

Family

ID=38217710

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0620243-8A BRPI0620243A2 (pt) 2005-12-23 2006-12-19 peptìdeo quimérico capaz de se ligar à pelo menos uma forma alélica da molécula hla-dr, composição farmaceutica e uso do peptìdeo

Country Status (12)

Country Link
US (1) US20090220533A1 (enExample)
EP (1) EP1978026B1 (enExample)
JP (1) JP2009520772A (enExample)
CN (1) CN101374857A (enExample)
AT (1) ATE502047T1 (enExample)
AU (1) AU2006329789A1 (enExample)
BR (1) BRPI0620243A2 (enExample)
CA (1) CA2634840A1 (enExample)
DE (1) DE602006020781D1 (enExample)
ES (1) ES2310072B1 (enExample)
RU (1) RU2008129731A (enExample)
WO (1) WO2007074188A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107375919B (zh) 2009-03-27 2022-07-29 台湾地区“中央研究院” 抗病毒免疫的方法和组合物
TWI537385B (zh) 2010-11-04 2016-06-11 中央研究院 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0735893B1 (en) * 1993-09-14 2008-11-26 Pharmexa Inc. Pan dr-binding peptides for enhancement of the immune response
EP0876398B1 (en) 1996-01-24 2002-07-17 Epimmune, Inc. Induction of immune response against desired determinants
US6413517B1 (en) * 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
CA2332786A1 (en) * 1998-05-29 1999-12-02 Epimmune Inc. Identification of broadly reactive dr restricted epitopes
FR2824326B1 (fr) * 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
US20040236514A1 (en) * 2001-12-13 2004-11-25 Lee Stephen C. Controlling distribution of epitopes in polypeptide sequences

Also Published As

Publication number Publication date
ATE502047T1 (de) 2011-04-15
US20090220533A1 (en) 2009-09-03
EP1978026B1 (en) 2011-03-16
CA2634840A1 (en) 2007-07-05
JP2009520772A (ja) 2009-05-28
WO2007074188A1 (es) 2007-07-05
EP1978026A4 (en) 2010-03-10
EP1978026A1 (en) 2008-10-08
CN101374857A (zh) 2009-02-25
DE602006020781D1 (en) 2011-04-28
AU2006329789A1 (en) 2007-07-05
ES2310072B1 (es) 2009-11-16
ES2310072A1 (es) 2008-12-16
RU2008129731A (ru) 2010-01-27

Similar Documents

Publication Publication Date Title
Sinigaglia The molecular basis of metal recognition by T cells
Gairin et al. Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes
ES2318848T3 (es) Peptidos que se unen a pan dr para potenciar la respuesta inmunitaria.
ES2679127T3 (es) Composición vacunal contra el cáncer
ES2402956T3 (es) Péptido con formación de dímeros reducida
ES2367640T3 (es) Péptidos con afinidad de unión aumentada para al menos tres moléculas de tipo hla-a3.
ES2573700T3 (es) Combinaciones de péptidos para vacunas contra la alergia a los gatos
US10059751B2 (en) Peptide combinations and uses thereof in treating dust mite allergy
Vergelli et al. T cell response to myelin basic protein in the context of the multiple sclerosis-associated HLA-DR15 haplotype: peptide binding, immunodominance and effector functions of T cells
BR112019018616A2 (pt) peptídeos e métodos para o tratamento de diabetes
JPH03503166A (ja) 抗ｈｉｖ応答を喚起する合成抗原
Myers et al. Characterization of a tolerogenic T cell epitope of type II collagen and its relevance to collagen-induced arthritis.
Vrtala et al. Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination
Jefferies et al. IFN-gamma-induced recognition of the antigen-processing variant CMT. 64 by cytolytic T cells can be replaced by sequential addition of beta 2 microglobulin and antigenic peptides.
BRPI0620243A2 (pt) peptìdeo quimérico capaz de se ligar à pelo menos uma forma alélica da molécula hla-dr, composição farmaceutica e uso do peptìdeo
JP7174492B2 (ja) Ｓ－アレスチンペプチドおよびその治療的使用
WO2005068632A1 (ja) ＨＬＡ−Ａ２４０２拘束性Ｅｐ−ＣＡＭ特異的ＣＴＬが認識するエピトープ・ペプチド及びその用途
JP4065322B2 (ja) 合成ペプチドおよびそれらを含有する医薬組成物
JP2010235607A (ja) 自己免疫疾患の診断薬と治療薬となるペプチド類
AU678372B2 (en) Synthetic peptides for the treatment of myasthenia gravis
CN117651711A (zh) 使用免疫原性肽的改进的治疗方法
AU1906592A (en) Peptides for use in induction of t cell activation against hiv-1
MX2008008036A (en) Novel t-helper antigenic determinant (thd) peptides
Liu et al. The immunostimulatory effect of bio-active peptide from pollen on murine and human lymphocytes
EP2227486B1 (en) Peptide analogues and conjugates thereof

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2214 DE 11/06/2013.